MENS vs NUVB vs CRL vs MEDP

For growth investors, Nuvation Bio Inc.

(NUVB) is the stronger pick with 699. 0% revenue growth year-over-year, versus -0. 9% for Charles River Laboratories International, Inc. (CRL). Medpace Holdings, Inc. (MEDP) offers the better valuation at 28. 1x trailing P/E (25. 2x forward), making it the more compelling value choice. Analysts rate Nuvation Bio Inc. (NUVB) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Charles River Laboratories International, Inc.

is actually cheaper at 16. 4x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Medpace Holdings, Inc.

(MEDP) delivered a total return of +159. 4%, compared to -79. 7% for Jyong Biotech Ltd. Ordinary Shares (MENS). Over 10 years, the gap is even starker: MEDP returned +1443% versus MENS's -79. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Medpace Holdings, Inc.

(MEDP) is the lower-risk stock at 1. 26β versus Jyong Biotech Ltd. Ordinary Shares's 2. 49β — meaning MENS is approximately 98% more volatile than MEDP relative to the S&P 500. On balance sheet safety, Nuvation Bio Inc. (NUVB) carries a lower debt/equity ratio of 3% versus 95% for Charles River Laboratories International, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Nuvation Bio Inc.

(NUVB) is pulling ahead at 699. 0% versus -0. 9% for Charles River Laboratories International, Inc. (CRL). On earnings-per-share growth, the picture is similar: Nuvation Bio Inc. grew EPS 71. 6% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, MEDP leads at 20. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Medpace Holdings, Inc.

(MEDP) is the more profitable company, earning 17. 8% net margin versus -325. 3% for Nuvation Bio Inc. — meaning it keeps 17. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MEDP leads at 21. 1% versus -338. 7% for NUVB. At the gross margin level — before operating expenses — NUVB leads at 86. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Charles River Laboratories International, Inc.

(CRL) trades at 16. 4x forward P/E versus 25. 2x for Medpace Holdings, Inc. — 8. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NUVB: 157. 3% to $12. 40.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Medpace Holdings, Inc.

(MEDP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26), +1443% 10Y return). Jyong Biotech Ltd. Ordinary Shares (MENS) carries a higher beta of 2. 49 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MEDP: +1443%, MENS: -79. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: MENS is a small-cap quality compounder stock; NUVB is a small-cap high-growth stock; CRL is a small-cap quality compounder stock; MEDP is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.